Iloperidone is atypical antipsychotic drug and its IUPAC name is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3- yl)-1- piperidinyl]propoxy]-3methoxyphenyl]ethanone. The literature reveals that few methods established for the quantification of Iloperidone in biological fluids. We have developed and validated a simple, sensitive and rapid method for the quantification of Iloperidone in spiked human plasma by using LC-MS/MS. The seperation conditions for iloperidone by using Hibar® Octadecasilanecolumn (15cm x 4.6mm; 5µm) as stationary phase. Mobile phase composed of cyanomethane and 10mM ammonium formate (pH adjusted to 4.0 using formic acid) in the ratio of 85:15(v/v) at a flow rate of 0.5 mL/min. Injection volume was 10µL, ambient lab condition and the run time was 5.00 minutes. The quantification of Iloperidone and IS were achieved in positive ion mode in MRM (Multiple Reaction Monitoring) with retention times approximately 2.05 and 3.55 mins respectively. The precursor to product ion transitions and collision energies for Iloperidone and IS were m/z: 427.20→261.00 and 361.20→342.95 respectively. The overall precision of the matrix factor determined at lowest concentration was found to be 98.42% and highest concentration was found to be 99.54%. The analyte peaks were free from interferences in plasma samples. The method was validated as per USFDA guidelines which shows a high degree of precision and accuracy. Limit of Detection of Iloperidone and Limit of Quantification was found to be 0.15 ng/mL and 0.5ng/mL respectively.

Iloperidone, Bioanalysis, LCMSMS-ESI, Human plasma, Bioanalytical validation